Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cyclophosphamide offers superior GVHD prophylaxis

Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Key clinical point: A cyclophosphamide-containing posttransplant regimen bested controls for reducing graft versus host disease rates.

Major finding: The hazard ratio for GVHD-free and relapse-free survival was 0.72 for those receiving cyclophosphamide, compared with controls (P = .04).

Study details: Randomized, controlled trial of 497 patients receiving one of three intervention arm posttransplant regimens for GVHD prophylaxis, or a control regimen of tacrolimus and methotrexate.

Disclosures: Dr. Bolaños-Meade reported serving on the data safety monitoring board of Incyte.

Source: Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Read the article.

Citation:

Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

This Week's Must Reads

Monetary support affects select prescribing, Mitchell AP et al. JAMA Intern Med. 2018 Apr 9. doi: 0.1001/jamainternmed.2018.0776

Best TKI options in ALL, Jabbour E et al. Clin Lymphoma Myeloma Leuk. 2018 18(4):257-65

2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

Blinatumomab eliminates residual B-cell ALL, Gökbuget N et al. Blood. 2018 Apr 5;131(14):1522-31.

Aryl hydrocarbon receptor antagonist boosts cord blood engraftment, Wagner J et al. 2018 Bone Marrow Transplant Tandem Meetings, Abstract 4.

Must Reads in Cellular Therapy

Aryl hydrocarbon receptor antagonist boosts cord blood engraftment, Wagner J et al. 2018 Bone Marrow Transplant Tandem Meetings, Abstract 4.

Cyclophosphamide offers superior GVHD prophylaxis, Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Harvest T cells before chemo for ALL, Barrett DM et al. AACR 2018, Abstract 1631

Gut microbiome affects transplant outcomes, Peled J et al. 2018 Bone Marrow Transplant Tandem Meetings, Abstract 3

New option for chronic graft vs. host, Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.